A pdrn anti-aging composition, a preparation method thereof, and application thereof

Abstract

The present application belongs to the technical field of skin care products, and particularly relates to a PDRN anti-aging composition, a preparation method thereof and application. The present application uses hydrolyzed sponges to open the absorption channels of the stratum corneum, and uses the specific proteins, polypeptides in hydrolyzed royal jelly protein and wheat glutelin and PDRN to form a stable molecular structure through van der Waals force, so as to enhance the stability of PDRN and promote the activity of PDRN. The high-energy phosphate bond of sodium mannose phosphate can enhance the activity of mitochondria, provide more energy for the penetration and absorption of PDRN and the exertion of efficacy, and tetrahydro methyl pyrimidine carboxylic acid is used to relieve the irritation of hydrolyzed sponges. Therefore, the PDRN anti-aging composition provided by the present application has a synergistic effect between the components. The data of the examples show that the PDRN anti-aging composition provided by the present application has good penetration and anti-aging effect.

Description

Technical Field

[0001] This invention belongs to the field of skin care technology, specifically relating to a PDRN anti-aging composition, its preparation method, and its application. Background Technology

[0002] Polydeoxyribonucleotide (PDRN) is a specific DNA fragment extracted from salmon reproductive cells or salmon seminal vesicles. It has low rejection rate and a 98% similarity to human DNA, which can effectively promote tissue repair and regeneration.

[0003] In recent years, the application of PDRN has expanded to the fields of medical aesthetics and skincare. Studies have shown that PDRN can exert multiple skincare activities: in anti-aging, it can promote collagen synthesis, inhibit the activity of metalloproteinases and elastases, achieve extracellular matrix remodeling, and combat skin aging; in photoaging protection, it can prevent photoaging through antioxidant and photoprotective effects; in whitening and fading spots, it can significantly reduce melanin production in melanocytes, inhibit tyrosinase activity, and regulate the expression of microphthalmia-associated transcription factor (MITF) and tyrosinase-associated protein-1 (TRP-1), thereby inhibiting melanin production and deposition at the root.

[0004] Despite PDRN's excellent skincare potential, in topical cosmetics (where the absorption of active ingredients requires penetration of the dense stratum corneum), PDRN, as a large molecule, has limited ability to penetrate the stratum corneum. The vast majority of PDRN remains on the skin surface, with only a very small portion potentially penetrating through appendages such as hair follicles and sebaceous glands, or intercellular spaces, making it difficult to achieve the desired effects. Summary of the Invention

[0005] In view of this, the present invention provides a PDRN anti-aging composition, its preparation method and application, and the PDRN anti-aging composition provided by the present invention has good permeability.

[0006] This invention provides a PDRN anti-aging composition, comprising the following components in weight percentage: PDRN 0.001~1%; Hydrolyzed sponge 0.01~2%; Hydrolyzed royal jelly protein 0.1-2%; Sodium mannose phosphate 0.1-5%; Wheat gluten 1-5%; Tetrahydromethylpyrimidine carboxylic acid 0.1-5%; 1,3-Propanediol 5%; 1,2-Pentanediol 5%; Carbomer 0.5%; Arginine 0.3%; Water balance.

[0007] Preferably, the product comprises the following components, by weight percentage: PDRN 0.001%; Hydrolyzed sponge 0.01%; Hydrolyzed royal jelly protein 0.1%; Sodium mannose phosphate 0.1%; Wheat gluten 1%; Tetrahydromethylpyrimidine carboxylic acid 0.5%; 1,3-Propanediol 5%; 1,2-Pentanediol 5%; Carbomer 0.5%; Arginine 0.3%; Water balance.

[0008] Preferably, the product comprises the following components, by weight percentage: PDRN 1%; Hydrolyzed sponge 1%; Hydrolyzed royal jelly protein 2%; Sodium mannose phosphate 5%; Wheat gluten 5%; Tetrahydromethylpyrimidine carboxylic acid 0.5%; 1,3-Propanediol 5%; 1,2-Pentanediol 5%; Carbomer 0.5%; Arginine 0.3%; Water balance.

[0009] Preferably, the product comprises the following components, by weight percentage: PDRN 0.2%; Hydrolyzed sponge 0.2%; Hydrolyzed royal jelly protein 1%; Sodium mannose phosphate 2%; Wheat gluten 3%; Tetrahydromethylpyrimidine carboxylic acid 0.5%; 1,3-Propanediol 5%; 1,2-Pentanediol 5%; Carbomer 0.5%; Arginine 0.3%; Water balance.

[0010] Preferably, the product comprises the following components, by weight percentage: PDRN 0.5%; Hydrolyzed sponge 0.5%; Hydrolyzed royal jelly protein 1.5%; Sodium mannose phosphate 3%; Wheat gluten 2%; Tetrahydromethylpyrimidine carboxylic acid 0.5%; 1,3-Propanediol 5%; 1,2-Pentanediol 5%; Carbomer 0.5%; Arginine 0.3%; Water balance.

[0011] Preferably, the product comprises the following components, by weight percentage: PDRN 0.8%; Hydrolyzed sponge 0.2%; Hydrolyzed royal jelly protein 1%; Sodium mannose phosphate 2%; Wheat gluten 4%; Tetrahydromethylpyrimidine carboxylic acid 0.5%; 1,3-Propanediol 5%; 1,2-Pentanediol 5%; Carbomer 0.5%; Arginine 0.3%; Water balance.

[0012] The present invention also provides a method for preparing the anti-aging composition described in the above technical solution, comprising the following steps: Carbomer and the first portion of water are mixed to obtain a carbomer premix; Arginine and the second portion of water are mixed a second time to obtain an arginine premix; PDRN and the remaining water are mixed a third time to obtain PDRN premix; Hydrolyzed sponge and 1,3-propanediol were mixed in a fourth batch to obtain a hydrolyzed sponge premix. Hydrolyzed royal jelly protein, sodium mannose phosphate, wheat gluten, tetrahydromethylpyrimidine carboxylic acid and 1,2-pentanediol were added to the carbomer premix in sequence for a fifth mixing to obtain the first mixture.

[0013] Add the first mixture to the PDRN premix and perform a sixth mixing to obtain the second mixture; A second mixture is added to the hydrolyzed sponge premix for a seventh mixing process to obtain a third mixture. The third mixture was added to the arginine premix solution for the eighth mixing to obtain the PDRN anti-aging composition.

[0014] Preferably, the first to eighth mixing is carried out under stirring conditions; the stirring speed is independently 40 rpm.

[0015] The present invention also provides the application of the anti-aging composition described in the above technical solution or the anti-aging composition prepared by the above preparation method in the preparation of skin anti-aging products, whitening and spot-fading products, phototherapy post-operative repair products or sensitive skin anti-inflammatory repair products.

[0016] This invention utilizes a hydrolyzed sponge to open up absorption channels in the stratum corneum. Unique proteins and peptides from hydrolyzed royal jelly and wheat gluten form a stable molecular structure with PDRN via van der Waals forces, enhancing PDRN stability and promoting PDRN activity. The high-energy phosphate bonds of sodium mannose phosphate enhance mitochondrial activity, providing more energy for PDRN penetration, absorption, and efficacy. Tetrahydromethylpyrimidine carboxylic acid is used to alleviate the irritation of the hydrolyzed sponge. Therefore, the components of the PDRN anti-aging composition provided by this invention have a synergistic effect. Data from the examples show that the PDRN anti-aging composition provided by this invention has good permeability and anti-aging effects. Detailed Implementation

[0017] This invention provides a PDRN anti-aging composition, comprising the following components in weight percentage: PDRN 0.001~1%; Hydrolyzed sponge 0.01~2%; Hydrolyzed royal jelly protein 0.1-2%; Sodium mannose phosphate 0.1-5%; Wheat gluten 1-5%; Tetrahydromethylpyrimidine carboxylic acid 0.1-5%; 1,3-Propanediol 5%; 1,2-Pentanediol 5%; Carbomer 0.5%; Arginine 0.3%; Water balance.

[0018] As one embodiment of the present invention, the PDRN anti-aging composition comprises 0.001 to 1% PDRN by weight percentage, specifically 0.005%, 0.2%, 0.5%, 0.7% or 1%.

[0019] In one embodiment of the present invention, the PDRN anti-aging composition comprises 0.01-2% hydrolyzed sponge by weight percentage, specifically 0.01%, 0.1%, 0.5%, 1% or 2%; In one embodiment of the present invention, the PDRN anti-aging composition comprises 0.1-2% hydrolyzed royal jelly protein by weight percentage, specifically 0.1%, 0.5%, 1%, 1.5%, or 2%. In one embodiment of the present invention, the PDRN anti-aging composition comprises 0.1-5% sodium mannose phosphate, specifically 0.1%, 1%, 2%, 3%, 4% or 5% by weight. In one embodiment of the present invention, the PDRN anti-aging composition comprises 1-5% wheat glutenin, specifically 1%, 2%, 3%, 4% or 5% by weight. In one embodiment of the present invention, the PDRN anti-aging composition comprises 0.1-5% tetrahydromethylpyrimidine carboxylic acid, specifically 0.1%, 0.5%, 1%, 3%, or 5% by weight. As one embodiment of the present invention, the PDRN anti-aging composition comprises 5% 1,3-propanediol by weight percentage.

[0020] As one embodiment of the present invention, the PDRN anti-aging composition comprises 5% 1,2-pentanediol by weight percentage.

[0021] As one embodiment of the present invention, the PDRN anti-aging composition comprises 0.5% carbomer by weight percentage.

[0022] As one embodiment of the present invention, the PDRN anti-aging composition comprises 0.3% arginine by weight percentage.

[0023] In one embodiment of the present invention, the PDRN anti-aging composition comprises, by weight percentage, the balance being water.

[0024] The present invention also provides a method for preparing the PDRN anti-aging composition described in the above technical solution, comprising the following steps: Carbomer and the first portion of water are mixed to obtain a carbomer premix; Arginine and the second portion of water are mixed a second time to obtain an arginine premix; PDRN and the remaining water are mixed a third time to obtain PDRN premix; Hydrolyzed sponge and 1,3-propanediol were mixed in a fourth batch to obtain a hydrolyzed sponge premix. Hydrolyzed royal jelly protein, sodium mannose phosphate, wheat gluten, tetrahydromethylpyrimidine carboxylic acid and 1,2-pentanediol were added to the carbomer premix in sequence for a fifth mixing to obtain the first mixture.

[0025] Add the first mixture to the PDRN premix and perform a sixth mixing to obtain the second mixture; A second mixture is added to the hydrolyzed sponge premix for a seventh mixing process to obtain a third mixture. The third mixture was added to the arginine premix solution for the eighth mixing to obtain the PDRN anti-aging composition.

[0026] In one embodiment of the present invention, the first to eighth mixing can be carried out under stirring conditions; the stirring speed can be 40 rpm independently.

[0027] The present invention also provides the application of the anti-aging composition described in the above-mentioned technical solutions in the preparation of skin anti-aging products, whitening and spot-fading products, phototherapy post-operative repair products, or sensitive skin anti-inflammatory repair products.

[0028] To further illustrate the present invention, the technical solutions provided by the present invention will be described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0029] Example Table 1. Mass percentage of each component in the compositions of the examples and comparative examples.

[0030] The preparation method involves mixing carbomer and a first portion of water (70% of the total water volume) according to the component contents in Table 1 to obtain a carbomer premix; mixing arginine and a second portion of water (10% of the total water volume) to obtain an arginine premix; mixing PDRN and the remaining water (20% of the total water volume) to obtain a PDRN premix; mixing hydrolyzed sponge and 1,3-propanediol to obtain a hydrolyzed sponge premix; sequentially adding hydrolyzed royal jelly protein, sodium mannose phosphate, wheat gluten, tetrahydromethylpyrimidine carboxylic acid, and 1,2-pentanediol to the carbomer premix to obtain a first mixture; adding the first mixture to the PDRN premix to obtain a second mixture; adding the second mixture to the hydrolyzed sponge premix to obtain a third mixture; and adding the third mixture to the arginine premix to obtain the PDRN anti-aging composition.

[0031] test I. Permeability Test (using tetrahydromethylpyrimidine carboxylic acid as the calibrator) 1. Test method: Refer to GB / T27818-2011 Laboratory Method for In Vitro Tests of Skin Absorption of Chemicals: NR-TW-ST01-Penetration Enhancement-Transdermal Absorption Test of Cosmetics.

[0032] 2. The reagents and consumables are as follows: Bitop AG, a supplier of ectoine (tetrahydromethylpyrimidine carboxylic acid). DPBS supplier Shanghai Titan Technology Co., Ltd. Shanghai Kaikai Technology & Trade Co., Ltd., a supplier of Bama piglet skin. Shanghai Titan Technology Co., Ltd., a supplier of disposable syringes Shanghai Titan Technology Co., Ltd. is a supplier of 0.22μm needle filters. Methanol supplier Shanghai Titan Technology Co., Ltd. 3. Experimental Procedure (1) Prepare 5mg / ml ectoine solution: Weigh 25mg ectoine and add it to a volumetric flask, then add ultrapure water to make up to volume and shake to mix evenly.

[0033] (2) Use cutting scissors to cut pig skin into small pieces of a fixed size, add them to DPBS solution for washing, and then use filter paper to blot dry. Divide the pig skin into experimental group and control group, with 3 pieces in each group. The experimental group is treated with a small amount of essence (0.5% ecoxib) for 2 minutes in advance, while the control group is not treated.

[0034] (3) Add receiving solution to the receiving chamber: Use a pipette to draw 6.0 mL of receiving solution (DPBS) and inject it into the receiving chamber, and place the matching magnetic stir bar in the receiving chamber.

[0035] (4) The test model was not fixed in place: The piglet skin was fixed between the diffusion chamber and the receiving chamber of the Franzcell diffusion cell, with the cuticle of the piglet skin facing the diffusion chamber and the dermis facing the supply chamber. After fixing the piglet skin, 1.0 mL of receiving solution (DPBS) was added to the sampling tube using a pipette according to the liquid level in the sampling tube, so that the dermis of the piglet skin was in close contact with the receiving solution, and the total volume of the receiving solution was 7.0 mL.

[0036] (5) Fix the Franzcell diffusion cell in the transdermal absorption diffusion apparatus, turn on the electromagnetic stirrer and stir at a speed of 300 rpm, maintain a constant temperature water bath of (32±1)℃, and ensure that there are no air bubbles in the water bath jacket.

[0037] (6) Sample loading: After the water bath temperature of the diffuser is constant, the sample loading process is carried out. The materials of Examples 1-5, Comparative Examples 1-2, and Ectoin solution are added to the supply tank respectively.

[0038] (7) Subcutaneous sample collection: At time points of 0h and 0.5h, 0.3mL of receiving fluid was drawn with a syringe and placed in a 1.5mL EP tube. Then, 0.3mL of DPBS solution was added to the receiving chamber with a syringe.

[0039] (8) The content of ectoin was quantitatively analyzed by sampling at each time point using high performance liquid chromatography (HPLC).

[0040] 4. Data processing: Based on the content of continuous testing, the transdermal absorption effect was compared. The data are shown in Table 2.

[0041] Table 2. Results of Transdermal Absorption Test

[0042] Note: Statistical analysis was performed using the t-est method. This indicates a significant difference compared to the control group (p < 0.05).

[0043] As shown in Table 1, compared with the ectoine control group, after 0.5 hours of treatment in Examples 1-5 and Comparative Examples 1-2, the concentration of ectoine in the receiving pool of Examples 2-5 and Comparative Example 1 increased significantly, showing a significant difference (P<0.05).

[0044] II. Anti-aging effect test 1. Test method: T / AHPCA 047—2023 Test method for anti-wrinkle and firming efficacy of cosmetics (rapid assay for elastase inhibition); Laboratory Methods: "NR-WI-TM19-Anti-aging-Firming-Based Elastase Activity Inhibition Test".

[0045] 2. Experimental Procedure 2.1 Test Principle A decline in collagen and elastin levels leads to clinical signs of aging such as loose, sagging skin and wrinkles. Elastase is a protease that hydrolyzes insoluble elastin, but it can also break down a wide range of proteins, including casein, gelatin, and hemoglobin. Therefore, inhibiting elastase secretion can reduce elastin degradation. The ability of a sample to inhibit elastase activity is evaluated using physicochemical methods to determine its anti-wrinkle effect.

[0046] 2.2 Reagents and consumables are listed in Table 3.

[0047] Table 3 Reagents and Consumables

[0048] 2.3 Experimental Procedure (1) Weigh tris(hydroxymethyl)aminomethane and sodium chloride, add ultrapure water to prepare a buffer solution with a concentration of 20 mM tris(hydroxymethyl)aminomethane and a concentration of 1 mol / L sodium chloride, and adjust the pH of the buffer solution to 7.5.

[0049] (2) Prepare elastase and elastase substrate solutions of 6 U / ml and 5 mg / ml respectively using buffer solution, and store them on ice. Set up sample group, positive control group and blank group respectively. The positive control group is elastase inhibitor solution (10 nM cevelextastat) and the blank group is buffer solution. Set up 3 wells in each group in parallel. Add 25 μl of test solution and 50 μl of enzyme solution to each well and shake at 37℃ for 5 minutes.

[0050] (3) Add 25 μl of elastase substrate solution to each test group and shake quickly to mix.

[0051] (4) The absorbance at 410 nm was continuously measured for 30 minutes using an enzyme-linked immunosorbent assay (ELISA) reader, and the results were analyzed.

[0052] 3. Data Processing: Based on continuous absorbance readings, a simulation curve was plotted and the growth rate M was determined. Then, the elastase activity inhibition rate was calculated. .

[0053] 4. Experimental Results Table 4. Experimental results on the inhibition of elastase activity by the samples.

[0054] Note: Use t The -test method is used for statistical analysis. This indicates a significant difference compared to the control group (p < 0.05). This indicates a significant difference compared to the control group, p<0.01.

[0055] As shown in Table 4, compared with the blank control group, the elastase inhibitor solution in the positive control group showed an elastase activity inhibition rate of 91% (p<0.01), confirming the effectiveness of the testing system. Compared with the blank control group, the elastase activity inhibition rates in Example 2 were 76% (p<0.01), in Example 3 65% (p<0.01), in Example 4 68% (p<0.01), and in Example 5 72% (p<0.01), showing significant differences. In summary, Examples 2-5 exhibit anti-wrinkle effects by inhibiting elastase activity.

[0056] Although the above embodiments have provided a detailed description of the present invention, they are only some embodiments of the present invention, and not all embodiments. People can obtain other embodiments based on these embodiments without creative effort, and these embodiments all fall within the protection scope of the present invention.

Claims

1. A PDRN anti-aging composition, characterized in that, It includes the following components by mass percentage: PDRN 0.001~1%; Hydrolyzed sponge 0.01~2%; Hydrolyzed royal jelly protein 0.1-2%; Sodium mannose phosphate 0.1-5%; Wheat gluten 1-5%; Tetrahydromethylpyrimidine carboxylic acid 0.1-5%; 1,3-Propanediol 5%; 1,2-Pentanediol 5%; Carbomer 0.5%; Arginine 0.3%; Water balance.

2. The PDRN anti-aging composition according to claim 1, characterized in that, It includes the following components by mass percentage: PDRN 0.001%; Hydrolyzed sponge 0.01%; Hydrolyzed royal jelly protein 0.1%; Sodium mannose phosphate 0.1%; Wheat gluten 1%; Tetrahydromethylpyrimidine carboxylic acid 0.5%; 1,3-Propanediol 5%; 1,2-Pentanediol 5%; Carbomer 0.5%; Arginine 0.3%; Water balance.

3. The PDRN anti-aging composition according to claim 1, characterized in that, It includes the following components by mass percentage: PDRN 1%; Hydrolyzed sponge 1%; Hydrolyzed royal jelly protein 2%; Sodium mannose phosphate 5%; Wheat gluten 5%; Tetrahydromethylpyrimidine carboxylic acid 0.5%; 1,3-Propanediol 5%; 1,2-Pentanediol 5%; Carbomer 0.5%; Arginine 0.3%; Water balance.

4. The PDRN anti-aging composition according to claim 1, characterized in that, It includes the following components by mass percentage: PDRN 0.2%; Hydrolyzed sponge 0.2%; 1% hydrolyzed royal jelly protein; Sodium mannose phosphate 2%; Wheat gluten 3%; Tetrahydromethylpyrimidine carboxylic acid 0.5%; 1,3-Propanediol 5%; 1,2-Pentanediol 5%; Carbomer 0.5%; Arginine 0.3%; Water balance.

5. The PDRN anti-aging composition according to claim 1, characterized in that, It includes the following components by mass percentage: PDRN 0.5%; Hydrolyzed sponge 0.5%; Hydrolyzed royal jelly protein 1.5%; Sodium mannose phosphate 3%; Wheat gluten 2%; Tetrahydromethylpyrimidine carboxylic acid 0.5%; 1,3-Propanediol 5%; 1,2-Pentanediol 5%; Carbomer 0.5%; Arginine 0.3%; Water balance.

6. The PDRN anti-aging composition according to claim 1, characterized in that, It includes the following components by mass percentage: PDRN 0.8%; Hydrolyzed sponge 0.2%; Hydrolyzed royal jelly protein 1%; Sodium mannose phosphate 2%; Wheat gluten 4%; Tetrahydromethylpyrimidine carboxylic acid 0.5%; 1,3-Propanediol 5%; 1,2-Pentanediol 5%; Carbomer 0.5%; Arginine 0.3%; Water balance.

7. A method for preparing the anti-aging composition according to any one of claims 1 to 6, characterized in that, Includes the following steps: Carbomer and the first portion of water are mixed to obtain a carbomer premix; Arginine and the second portion of water are mixed a second time to obtain an arginine premix; PDRN and the remaining water are mixed a third time to obtain PDRN premix; Hydrolyzed sponge and 1,3-propanediol were mixed in a fourth batch to obtain a hydrolyzed sponge premix. Hydrolyzed royal jelly protein, sodium mannose phosphate, wheat gluten, tetrahydromethylpyrimidine carboxylic acid and 1,2-pentanediol were added to the carbomer premix in sequence for a fifth mixing to obtain the first mixture. Add the first mixture to the PDRN premix and perform a sixth mixing to obtain the second mixture; A second mixture is added to the hydrolyzed sponge premix for a seventh mixing process to obtain a third mixture. The third mixture was added to the arginine premix solution for the eighth mixing to obtain the PDRN anti-aging composition.

8. The preparation method according to claim 7, characterized in that, The first to eighth mixtures were carried out under stirring conditions.

9. The use of the anti-aging composition according to any one of claims 1 to 6 or the anti-aging composition according to claim 7 or 8 in the preparation of skin anti-aging products, whitening and spot-fading products, phototherapy post-operative repair products or sensitive skin anti-inflammatory repair products.

Images